Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziprasidone as Adjuvant for Antipsychotic-Associated Metabolic Issues in Schizophrenia
NCT00351000Phase 4Completed
- Sponsor
- North Suffolk Community Services
- Start
- Jan 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ziprasidone in schizophrenia, schizoaffective disorder, type 2 diabetes mellitus (T2DM), impaired fasting glucose (IFG), insulin resistance (IR), sponsored by North Suffolk Community Services. Started Jan 2005; status: completed.
02
Drugs
ziprasidone
03
Conditions
schizophreniaschizoaffective disordertype 2 diabetes mellitus (T2DM)impaired fasting glucose (IFG)insulin resistance (IR)
Beyond the preview
Go deeper on NCT00351000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00351000.